Giant left ventricular rhabdomyoma treated successfully with everolimus: case report and review of literature

Cardiol Young. 2018 Jul;28(7):903-909. doi: 10.1017/S1047951118000598. Epub 2018 May 15.


IntroductionIntracardiac rhabdomyomas can cause severe ventricular dysfunction and outflow tract obstruction.Case reportA term newborn infant with antenatal diagnosis of giant left ventricle rhabdomyoma presented with cardiac failure and duct-dependent systemic circulation after birth. She was treated successfully with everolimus, showing decrease in tumour size and improvement in left ventricular ejection fraction.DiscussionTumour regression rate was 0.32 cm2/day and improved to 0.80 cm2/day with the use of everolimus. Herein we report a newborn with inoperable giant left ventricular cardiac rhabdomyoma and significant regression of the tumour. To our knowledge, this is the largest left ventricular rhabdomyoma reported. A review of the literature was undertaken for comparison.

Conclusion: Everolimus has proven to be efficacious in size reduction of cardiac rhabdomyomas in cases when surgical resection is not possible.

Keywords: Rhabdomyoma; everolimus; newborn; sirolimus.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Echocardiography
  • Everolimus / therapeutic use*
  • Female
  • Heart Failure / etiology
  • Heart Neoplasms / diagnostic imaging
  • Heart Neoplasms / drug therapy*
  • Heart Ventricles / drug effects
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Prenatal Diagnosis
  • Rhabdomyoma / diagnostic imaging
  • Rhabdomyoma / drug therapy*
  • Treatment Outcome


  • Antineoplastic Agents
  • Everolimus